domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -10,17 +10,10 @@ agent: vida
 sourced_from: health/2026-04-23-glp1-substance-use-disorder-33-trials.md
 scope: causal
 sourcer: PubMed/ClinicalTrials.gov systematic review
-challenges:
-- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
-related:
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
-- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
-supports:
-- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment
-- Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery
-reweave_edges:
-- The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24
-- Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24
+challenges: ["medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm"]
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement"]
+supports: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery"]
+reweave_edges: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24"]
 ---
 
 # GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use
@@ -33,3 +26,9 @@ A systematic review of ClinicalTrials.gov identified 33 registered trials examin
 **Source:** Zhu et al., Science 2025, Vol. 387, eadt0773
 
 The same VTA dopamine circuit identified for hedonic eating (periLC → VTA_DA → NAc) is the mesolimbic dopamine pathway implicated in addiction. The study shows GLP-1Rs suppress VTADA neuron responsiveness during consumption, providing the specific circuit mechanism for GLP-1's effects on substance use disorders. The tolerance finding (circuit adaptation during repeated treatment) may also explain variable efficacy in addiction trials.
+
+## Supporting Evidence
+
+**Source:** eClinicalMedicine (Lancet) 2025 meta-analysis
+
+Systematic review and meta-analysis of 14 studies (n=5,262,278) found mean AUDIT score reduction of −7.81 points (95% CI −9.02 to −6.60), which is clinically meaningful—moving patients from hazardous to non-hazardous drinking levels. Pooled observational studies showed 36% lower rate of alcohol-related events (HR 0.64, 95% CI 0.59–0.69). Individual RCTs with semaglutide showed significant effects, though pooled RCT analysis was non-significant due to heterogeneity (I²=87.5%) and small-sample pooling. Semaglutide and liraglutide showed strongest and most consistent reductions across drinking days, units per drinking day, and cravings.

inbox/archive/health/2026-04-24-eclinmed-glp1-alcohol-meta-analysis-2025.md

@@ -7,9 +7,12 @@ date: 2025
 domain: health
 secondary_domains: []
 format: peer-reviewed study
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-24
 priority: high
 tags: [glp-1, alcohol-use-disorder, AUD, meta-analysis, systematic-review, semaglutide, liraglutide, AUDIT, addiction, reward-circuit]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content